MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Cerus Corporation DPO Ratio 2011-2025 | CERS
Annual DPO Ratio Cerus Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 242 | 215 | 178 | 154 | 81.2 | 170 | 91.6 | 127 | 92.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 242 | 81.2 | 150 |
Quarterly DPO Ratio Cerus Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 148 | 159 | 192 | - | 202 | 228 | 254 | - | 267 | 250 | 221 | - | 208 | 220 | 184 | - | 187 | 230 | - | - | - | - | - | - | 85.6 | - | - | - | 158 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 267 | 85.6 | 200 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
71.6 | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
887 | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
405 | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
AstraZeneca PLC
AZN
|
265 | $ 90.34 | -1.28 % | $ 96.9 B |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
28.5 | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
54.4 | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
65.4 | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
186 | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
140 | - | 0.59 % | $ 63 K | USA |
 |
Catalyst Biosciences
CBIO
|
18.8 | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
90.1 | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
29.9 | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Caladrius Biosciences
CLBS
|
51.2 | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
6.17 K | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Clovis Oncology
CLVS
|
236 | - | -7.23 % | $ 13 M | USA |
 |
Benitec Biopharma
BNTC
|
-556 | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
2.2 K | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
199 | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
52.8 | $ 10.89 | -0.09 % | $ 1.42 B | USA |